Synairgen

("Synairgen" or the "Company")

Admission Statement

Southampton, UK – 8 May 2025: The Board of Synairgen, a UK-based respiratory biotech company, announces the admission of its Ordinary Shares to trading on Asset Match ahead of its first auction.

It is intended that the first auction in the Company's shares will be held in September 2025. Thereafter, auctions are expected to be held twice a year. More information, including exact auction dates and details on how to buy and sell, are available on the company profile page.

The Directors of the Company are:
Mark Parry-Billings, *(Chairman)*
Richard Marsden, *(Chief Executive Officer)*
Joseph Colliver, *(Chief Financial Officer)*
Martin Murphy, *(Non-Executive Director)*
John Bradshaw, *(Non-Executive Director)*

Registered office:
Mailpoint 810, Southampton General Hospital, Tremona Road, Southampton SO16 6YD.

Joseph Colliver, CFO of Synairgen, commented:
"The Board is pleased to be working with Asset Match to provide ongoing liquidity for our shareholders and a platform for trading shares. We believe that the trading platform offers the capabilities to enable a simple continuation of trading of our shares as a private company."

1. Company Description
Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need in mechanically-ventilated patients in the intensive care unit setting.

SNG001 has been tested in several clinical studies in both out-patient and hospital settings and was found to boost lung antiviral responses, accelerate viral clearance from the lungs, be well tolerated and show potential for clinical benefit in patients with various respiratory infections.

2. Strategy and Prospects

Synairgen has completed a review of data from previous trials of SNG001, epidemiological data, commercial factors and unmet clinical need, concluding that mechanically ventilated patients in intensive care are the

most appropriate group to target in the next clinical trial. With only one antiviral drug approved for adults in the US (remdesivir for COVID-19) for use in mechanically ventilated patients, these difficult and expensive to treat patients are underserved with currently available antiviral treatments and mortality remains high in the range of 25-45 per cent. Subject to regulatory approvals, Synairgen plans to initiate a Phase 2 clinical trial (INVENT) in mechanically ventilated patients with confirmed respiratory viral infections during this year.

3. Board of Directors

Brief biographies of the Directors of the Company are set out below.

Mark Parry-Billings (Chairman)

Dr. Mark Parry-Billings joined Synairgen in October 2024 as Chairman of the Board of Directors. Mark is an accomplished international biotech and pharmaceutical executive with a successful track record of more than 30 years in leadership and senior R&D roles. Most recently, he served as Global Head of Drug Development at Chiesi. Prior to this, he served as CEO of Topigen Pharmaceuticals until its acquisition by Pharmaxis in 2010. Mark has deep expertise in respiratory therapeutics and drug delivery to the lungs, having led multiple novel assets from early stage through clinical development to market approval, with a primary focus on inhaled drug delivery.

Richard Marsden (Chief Executive Officer)

Richard Marsden has led Synairgen as Chief Executive Officer since September 2009, following roles as General Manager and Managing Director. Between 1998 and 2003 Richard worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

Joseph Colliver (Chief Financial Officer)

Joseph Colliver joined the business as Chief Financial Officer in October 2023. Joseph is a Fellow Chartered Accountant with listed company, finance, commercial and consulting experience. Prior to Synairgen, he held positions as executive and non-executive directors of listed early-stage life sciences companies, where Joseph led financial reporting, M&A, strategy and regulatory / corporate governance. Prior to this, Joseph spent ten years in senior leadership roles in the Kantar division of WPP PLC, including CFO at Kantar Futures, and Global Commercial Director of TNS, a multi-billion-dollar global market research agency. Joseph qualified as a chartered accountant in the audit practice of Mazars LLP.

Martin Murphy (Non-Executive Director)

Martin Murphy joined Synairgen as Non-Executive Director in January 2025. Martin is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.

John Bradshaw (Non-Executive Director)

John Bradshaw is a Chartered Accountant with more than 30 years post-qualification experience working at Board level in UK listed companies, venture capital backed companies and partnerships including Chair of Audit Committee for two AIM listed companies and Chief Financial Officer of Syncona Investment Management

Limited, the investment manager of Syncona Limited, a FTSE250 healthcare investment company.

4. Share capital and significant shareholders

At 8 April 2025, the Company's issued share capital consisted of 1,102,660,697 Ordinary Shares with a nominal value of 1 pence each, each share having equal voting rights.

The Company does not hold any Ordinary Shares in treasury and therefore the number of Ordinary Shares with voting rights is 1,102,660,697.

The Ordinary Shares are not admitted to trading on any exchange or trading platform other than Asset Match, having exited the Alternative Investment Market (AIM) effective 9th April 2025.

The Company has been notified that the following shareholder(s) hold 3% or more of the issued share capital of the company:

Name of shareholder	*Number of Ordinary Shares*	*Percentage holding*
TFG Asset Management UK LLP	958,000,000	86.9%

5. Financial statements

The Company's latest interim results for the 6 months period ended 30 June 2024 can be accessed on the company profile page.

6. Legal and Arbitration Proceedings

During the 12 months preceding the date of this document, neither the Company nor any of its subsidiaries has been engaged in or is currently engaged in any litigation or arbitration proceedings which have been formally issued or which may have had in the recent past a significant effect on the financial position of the Company. The Company confirms that it has received correspondence from certain shareholders, in which some raise concerns around the recent fundraising and others have made various unsubstantiated allegations against both the Company and members of the Board to which its legal advisers are robustly responding. No legal proceedings have been formally issued. The Company does not currently anticipate that these complaints will have a material adverse effect on its business, operations, or financial condition.

7. Responsibility Statement

The Directors of Synairgen plc, as set about above, accept responsibility for the information contained within this document. To the best of the knowledge and belief of the directors (who have taken reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

REMINDER: It is intended that the first auction in the Company's shares will be held in September 2025. More information, including exact auction dates and details on how to buy and sell, will be provided via the Company's auction page.

-- ENDS --